Suppr超能文献

脑脊液生物标志物与淀粉样 PET 检测在 MCI 队列中的一致性和诊断准确性。

CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort.

机构信息

Department of Medicine and Surgery, Section of Neurology, Azienda Ospedaliero-Universitaria, Via Gramsci, 14, 43126, Parma, Italy.

Alzheimer Center, Briolini Hospital, Gazzaniga, Bergamo, Italy.

出版信息

Acta Neurol Belg. 2019 Sep;119(3):445-452. doi: 10.1007/s13760-019-01112-8. Epub 2019 Mar 7.

Abstract

Brain amyloid deposition is one of the main hallmarks of Alzheimer's disease (AD) and two approaches are available for assessing amyloid pathology in vivo: cerebrospinal fluid (CSF) biomarkers levels and amyloid load visualized by amyloid beta positron emission tomography imaging (Amy-PET) probes. We aimed to investigate the concordance between CSF biomarkers and Amy-PET in a memory clinic cohort. Moreover, using a proper clinical follow-up, we wanted to assess the diagnostic accuracy of CSF and PET biomarkers in predicting the progression of patients with mild cognitive impairment (MCI) to AD dementia. We included 31 MCI patients who underwent [18F]florbetaben PET and CSF sampling (Aβ1-42, t-Tau, p-Tau). A semiquantitative visual scan assessment was used to quantify amyloid deposition in 5 brain regions, rating from 1 (negative), to 2 and 3 (positive). CSF biomarkers were considered abnormal if: Aβ1-42 < 600 pg/ml, p-Tau/Aβ1-42 > 0.08 and t-Tau/Aβ1-42 > 0.52. We also applied less lenient cutoffs of 550 pg/ml and 450 pg/ml for Aβ1-42. The concordance rate was 77% between Amy-PET and CSF Aβ1-42 levels, and 89% between Amy-PET and p-Tau/Aβ1-42 and t-Tau/Aβ1-42. According to the clinical follow-up, Amy-PET (sensitivity [SE] 93.7%, specificity [SP] 80%) exhibited the best diagnostic accuracy in discriminating AD from non-AD, followed by p-Tau/Aβ1-42 ratio and t-Tau/Aβ1-42 ratio (SE 93.7%, SP 66.6%), and Aβ1-42 levels (SE 81%, SP 60%). The regional uptake of [18F]florbetaben PET in the precuneus and the striatum showed the best SP (86.6%). In discordant cases, the clinical diagnosis was most often in agreement with PET results. In general, concordance between CSF biomarkers and Amy-PET was good, especially when the ratios between CSF amyloid and Tau biomarkers were used. However, Amy-PET proved to be superior to CSF Aβ1-42 in terms of diagnostic accuracy for AD, with the possibility to further increase its specificity by focusing the analysis in specific areas such as the precuneus/posterior cingulate cortex and the striatum.

摘要

脑淀粉样蛋白沉积是阿尔茨海默病(AD)的主要标志之一,有两种方法可用于评估体内的淀粉样蛋白病理学:脑脊液(CSF)生物标志物水平和通过淀粉样β正电子发射断层扫描成像(Amy-PET)探针可视化的淀粉样蛋白负荷。我们旨在研究记忆诊所队列中 CSF 生物标志物与 Amy-PET 之间的一致性。此外,通过适当的临床随访,我们希望评估 CSF 和 PET 生物标志物在预测轻度认知障碍(MCI)患者向 AD 痴呆进展方面的诊断准确性。我们纳入了 31 名接受 [18F]florbetaben PET 和 CSF 采样(Aβ1-42、t-Tau、p-Tau)的 MCI 患者。使用半定量视觉扫描评估来量化 5 个脑区的淀粉样蛋白沉积,评分从 1(阴性)到 2 和 3(阳性)。如果 CSF 生物标志物:Aβ1-42<600 pg/ml、p-Tau/Aβ1-42>0.08 和 t-Tau/Aβ1-42>0.52,则认为异常。我们还应用了更宽松的 Aβ1-42 截止值为 550 pg/ml 和 450 pg/ml。Amy-PET 与 CSF Aβ1-42 水平之间的一致性率为 77%,Amy-PET 与 p-Tau/Aβ1-42 和 t-Tau/Aβ1-42 之间的一致性率为 89%。根据临床随访,Amy-PET(灵敏度 [SE] 93.7%,特异性 [SP] 80%)在区分 AD 与非 AD 方面表现出最佳的诊断准确性,其次是 p-Tau/Aβ1-42 比值和 t-Tau/Aβ1-42 比值(SE 93.7%,SP 66.6%),以及 Aβ1-42 水平(SE 81%,SP 60%)。[18F]florbetaben PET 在楔前叶和纹状体的摄取显示出最佳的 SP(86.6%)。在不一致的情况下,临床诊断通常与 PET 结果一致。一般来说,CSF 生物标志物与 Amy-PET 之间的一致性良好,尤其是当 CSF 淀粉样蛋白与 Tau 生物标志物的比值被使用时。然而,Amy-PET 在 AD 的诊断准确性方面优于 CSF Aβ1-42,通过将分析集中在楔前叶/后扣带回和纹状体等特定区域,有可能进一步提高其特异性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验